Department of Diagnostic Pathology, Kochi Red Cross Hospital, Kochi, Japan.
Histol Histopathol. 2012 Aug;27(8):969-74. doi: 10.14670/HH-27.969.
Multilocular cystic renal cell carcinoma (MCRCC) accounts for approximately 1 to 2% of all renal tumors. This tumor is currently classified as a subtype of clear cell RCC. Clinically, the majority of these tumors are incidentally found. Macroscopically, the tumor is well demarcated and consists of various-sized cysts. The fibrous septa are generally thin and there is no discernible expansile nodule. Microscopically, the cyst walls are lined with tumor cells with clear to occasionally slightly eosinophilic cytoplasm. The Fuhrman nuclear grade is generally low and usually corresponds to grade 1. The deletion of chromosome 3p was identified in most tumors using FISH analysis and VHL gene mutation was identified in 25% of MCRCC. As MCRCC generally exhibits a low stage of TNM classification, the great majority of these tumors have a favorable clinical course. To date, there are no reports of metastasis, vascular invasion or sarcomatoid change in MCRCC. Accordingly, nephron sparing surgery is first recommended as a therapeutic strategy.
多房性囊性肾细胞癌(MCRCC)约占所有肾肿瘤的 1%至 2%。这种肿瘤目前被归类为透明细胞肾细胞癌的一个亚型。临床上,大多数此类肿瘤是偶然发现的。大体上,肿瘤边界清楚,由大小不一的囊肿组成。纤维性隔膜通常较薄,没有明显的膨胀性结节。镜下,囊壁衬有肿瘤细胞,胞浆透明至偶尔稍嗜酸性。Fuhrman 核分级通常较低,通常对应于 1 级。使用 FISH 分析发现大多数肿瘤存在 3p 染色体缺失,25%的 MCRCC 存在 VHL 基因突变。由于 MCRCC 通常表现为 TNM 分类的低分期,大多数此类肿瘤具有良好的临床病程。迄今为止,MCRCC 没有转移、血管侵犯或肉瘤样变的报告。因此,建议首先采用保肾手术作为治疗策略。